Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19062561 | 1.00 | ATM (0.35) | ATMDPP4DPP8DPP7HDAC4 | |
| SCHEMBL14024065 | 0.86 | CYP2A6 (0.44) | CYP17A1CYP2A6 | |
| SCHEMBL19062805 | 0.86 | CYP2A6 (0.44) | CYP17A1CYP2A6 | |
| SCHEMBL20026159 | 0.85 | MAPT (0.36) | — | |
| SCHEMBL19063237 | 0.81 | PIK3CD (0.35) | — | |
| SCHEMBL20026213 | 0.81 | PIK3CD (0.35) | — | |
| SCHEMBL20026099 | 0.81 | AKT2 (0.49) | — | |
| SCHEMBL19062436 | 0.81 | PIK3CD (0.35) | — | |
| SCHEMBL20026369 | 0.80 | HDAC4 (0.36) | HDAC4AAK1 | |
| SCHEMBL17490458 | 0.80 | MET (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | ATM 4100/4885DPP4 229/4885DPP8 216/4885 |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | ATM 4100/4885DPP4 229/4885DPP8 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.